Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

MIRM earnings analysis

Filed May 6, 2026 · Our reading of the company's report

The latest report

In its Q1 2026 report, Mirum Pharmaceuticals delivered a notable increase in revenue, reaching $159.9 million, up from $111.6 million in Q1 2025, driven by strong sales of Livmarli and the Bile Acid Medicines. Despite a…

Read full summary

In its Q1 2026 report, Mirum Pharmaceuticals delivered a notable increase in revenue, reaching $159.9 million, up from $111.6 million in Q1 2025, driven by strong sales of Livmarli and the Bile Acid Medicines. Despite a significant net loss of $790.2 million, attributed to heightened R&D expenses and one-time costs related to the Bluejay Acquisition, the company raised its full-year revenue guidance, projecting sales between $660 million and $680 million.

Read the original on SEC.gov

Reported figures

Segment
Livmarli sales: $113.8 million, Bile Acid Medicines: $46.1 million

What stood out

  • Revenue Growth of 43.3% YoY

    Reported revenue of $159.9 million in Q1 2026, up from $111.6 million in Q1 2025.

  • Narrowed Loss per Share

    Loss per share was -$13.43, significantly narrower than the expected loss of -$0.36.

  • Increased Guidance

    Full-year revenue guidance raised to $660M-$680M, up from prior guidance.

  • Strong Cash Position

    Unrestricted cash increased to $420.6 million as of March 31, 2026.

  • Dramatic increase in R&D expenses

    R&D expenses surged to $97.9 million from $41.0 million in Q1 2025.

  • Successful Acquisition Impact

    The Bluejay Acquisition significantly expands the drug portfolio, including brelovitug.

What to watch

  • Substantial Net Loss

    Net loss increased to $790.2 million in Q1 2026, up from $14.7 million in Q1 2025.

  • High Operating Expenses

    Total operating expenses reached $949.3 million for Q1 2026, largely due to increased R&D costs.

  • Intellectual Property Risks

    Potential challenges to patents may threaten the competitive edge of Livmarli and volixibat.

Management's outlook

Increased full-year revenue guidance to $660M-$680M from prior guidance.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.